Peptide News Digest

#Peptide-Immunotherapy

2 stories

Clinical Trials · View digest

BriaCell Announces Six Bria-IMT Peptide Immunotherapy Presentations at ASCO 2026 Including 12- and 24-Month Survival Update

BriaCell announced April 27 that its Bria-IMT cell-based peptide immunotherapy will be featured in three poster presentations and three publication-only abstracts at the 2026 ASCO Annual Meeting (May 29–June 2, Chicago). Highlights include 12- and 24-month overall survival data with Bria-IMT plus checkpoint inhibition in advanced metastatic breast cancer, an updated quality-of-life and tolerability analysis, and a randomized Bria-ABC Phase 3 blood-biomarker progression-free survival readout. Three publication-only abstracts cover the second-generation BC1 platform, multi-analyte liquid biopsy stratification, and PD-L1 monitoring in circulating cancer-associated cells.

Clinical Trials · View digest

Enara Bio Debuts ENA101, First-in-Class DARKFOX-Targeting Peptide T-Cell Engager at AACR

Enara Bio presented ENA101 at AACR 2026 on April 20, a first-in-class bispecific T-cell engager targeting DARKFOX — a novel cancer-specific 'dark antigen' peptide presented by HLA-A*03:01 and expressed in multiple solid tumors. Preclinical data showed low-picomolar potency and complete tumor regression in xenograft models with once-weekly dosing. IND submission planned for 2H 2026.